Generate a tailored SOP for Dr. Greg Smith. Improve your application with a focused, well-structured draft.
Greg Smith is an Associate Professor in the School of Biomedical Sciences at the University of New South Wales. His research focuses on understanding how antipsychotic drugs, such as olanzapine and clozapine, affect glucose metabolism in individuals with schizophrenia. His work revealed significant insights into the mechanisms by which these drugs could induce diabetes amongst users. Smith's research particularly emphasizes the role of retinol-binding protein-4 (RBP4) in glucose production and cellular signaling events in the liver, showing that elevated RBP4 levels are associated with obesity and diabetes. Following bariatric surgery, RBP4 levels significantly decrease alongside blood glucose levels, underscoring its potential role in metabolic disorders. Moreover, he has been exploring the interleukin-6 (IL-6) signaling pathway's influence on hepatic glucose production, particularly its regulatory function in response to exercise. His contributions to the field have been recognized through various honors, including the Foundation Science and Technology Fellowship in New Zealand from 2012 to 2014.
University of New South Wales • Sydney, Australia
Conducting research on the effects of schizophrenia medications on glucose metabolism.
Includes Business Intelligence, Enterprise Systems, and Cybersecurity Management streams.